Business
PAOG Announces Analyst Report Update With $0.015 PPS 12-Month Target For New Cannabis Pharma Business
PAOG Announces Analyst Report Update With $0.015 PPS 12-Month Target For New Cannabis Pharma Business.
About this update from Pao Group, Inc.
[{"type":"text","content":"\n\n\n\nPAOG Announces Analyst Report Update With $0.015 PPS 12-Month Target For New Cannabis Pharma Business\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nPAOG Announces Analyst Report Update With $0.015 PPS 12-Month Target For New Cannabis Pharma Business\nPR Newswire\nSANDUSKY, Ohio, Sept. 8, 2020\n\n\n\nSANDUSKY, Ohio, Sept. 8, 2020 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today announced Goldman Small Cap Research has published an analyst research report update.  PAOG has recently entered the cannabis biopharmaceutical sector through two recent acquisitions.  The company acquired a cannabis cultivation business from Puration, Inc. (PURA).  From Kali-Extracts (KALY), PAOG acquired a proprietary CBD extract derived from a patented extraction process and formulated for the treatment of respiratory disorders. \nPAOG's recently acquired proprietary formulations are derived from a patented cannabis extraction process - U.S. Patent No. 9,199,960 entitled, \"METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.\" The formulation tradename is RespRx.  The RespRx CBD Biopharma treatment targets multiple respiratory-related diseases with a concentration on treating symptoms of Chronic Obstructive Pulmonary Disease (COPD).\nGoldman Small Cap Research Excerpt:\n\"PAO Group currently trades above its 50-day and 200-day moving averages. This bullish status, along with its recently updated financials reporting, should prompt the shares to reach new levels. Moreover, a review of the financials lends us greater confidence in the Company's R&D financing capabilities and the achievement of key milestones. Thus, we have now introduced a 12-month target of $0.015, a nearly 5x return from current levels.\"\nSee the full Goldman Small Cap Research Update:PAOG – Introducing Price Target For Emerging CBD Pharma\nThe original Goldman Small Cap Research Report can be reviewed at:Under The Radar CBD Pharma Player Could Offer Major Upside\nLearn more at: www.paogroupinc.com.\n­Forward-Looking Statements: Certai...